HW
SCLN

Hancock Whitney’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Hancock Whitney’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-82,248
Closed -$571K – 589
2015
Q3 		$571K Buy
+82,248
New +$704K 0.02% 422

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hancock Whitney's SCLN Position: Q4 2015 in Review

Hancock Whitney sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2015, closing a stake of 82,248 shares — an estimated $571K sold.

Hancock Whitney first reported a position in SCLN in Q3 2015 and held it in 1 quarter. The position peaked at $571K in Q3 2015. 133 funds tracked by Wall St. Rank hold SCLN as of Q4 2015.

  • Hancock Whitney reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Hancock Whitney sold 82,248 Sciclone Pharmaceuticals Inc shares in Q4 2015, an estimated $571K.
  • Hancock Whitney first reported a position in Sciclone Pharmaceuticals Inc in Q3 2015 and held it in 1 quarter.
  • Hancock Whitney's Sciclone Pharmaceuticals Inc position peaked at $571K in Q3 2015.
  • 133 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2015.

Based on Hancock Whitney's 13F filing for Q4 2015, filed 12 Feb 2016.